1. Home
  2. CURV vs FULC Comparison

CURV vs FULC Comparison

Compare CURV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

HOLD

Current Price

$2.25

Market Cap

253.3M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.72

Market Cap

285.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURV
FULC
Founded
2001
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.3M
285.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
CURV
FULC
Price
$2.25
$3.72
Analyst Decision
Hold
Hold
Analyst Count
7
5
Target Price
$2.17
★ $3.67
AVG Volume (30 Days)
146.5K
★ 1.3M
Earning Date
12-02-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.06
N/A
Revenue
★ $1,000,092,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.63
N/A
P/E Ratio
$39.17
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.94
$2.83
52 Week High
$2.86
$15.74

Technical Indicators

Market Signals
Indicator
CURV
FULC
Relative Strength Index (RSI) 44.89 46.26
Support Level $2.26 $3.62
Resistance Level $2.32 $3.91
Average True Range (ATR) 0.13 0.06
MACD -0.02 -0.00
Stochastic Oscillator 3.23 44.83

Price Performance

Historical Comparison
CURV
FULC

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: